Search results for "withholding treatment"

showing 10 items of 17 documents

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation

2013

BACKGROUND & AIMS: Histological assessment of fibrosis progression is currently performed by staging systems which are not continuous quantitative measurements. We aimed at assessing a quantitative measurement of fibrosis collagen proportionate area (CPA), to evaluate fibrosis progression and compare it to Ishak stage progression. METHODS: We studied a consecutive cohort of 155 patients with recurrent HCV hepatitis after liver transplantation (LT), who had liver biopsies at one year and were subsequently evaluated for progression of fibrosis using CPA and Ishak staging, and correlated with clinical decompensation. The upper quartile of distribution of fibrosis rates (difference in CPA or Is…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyLiver transplantationGastroenterologySeverity of Illness IndexCohort StudiesYoung AdultFibrosisRecurrenceRisk FactorsInternal medicineSeverity of illnessBiopsyAzathioprinemedicineImage Processing Computer-AssistedHumansDecompensationAgedHepatitisHepatologymedicine.diagnostic_testliver transplantationbusiness.industryHepatitis CMiddle Agedmedicine.diseaseHepatitis CSurgeryLiverWithholding TreatmentDisease ProgressionRegression AnalysisFemaleCollagenbusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Time course of adverse events most commonly associated with topiramate for migraine prevention

2007

The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double-blind, placebo-controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in/=2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double-blind, placebo-controlled, and 26-week trials. The pooled population comprised all randomized patients who reported safety data during the double-blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4-week titration period and a 22-week maintenance period. Incidence, time to onset, and cumulative mean rate of …

AdultMaleTopiramateTime FactorsNauseaMigraine DisordersPopulationFructosePlaceboTimelaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialTopiramatelawmedicineHumansParesthesiaeducationFatigueeducation.field_of_studyDose-Response Relationship Drugbusiness.industryNauseaMiddle Agedmedicine.diseaseAnorexiaDiscontinuationWithholding TreatmentNeurologyTolerabilityMigraineAnesthesiaPatient ComplianceAnticonvulsantsFemaleNeurology (clinical)medicine.symptomCognition Disordersbusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

2008

Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 microg/week) and ribavirin (1000 or 1200 mg/day); those with viral clearance at week 4 were randomized …

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeChronic hepatitis CAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundVirologyInternal medicineRibavirinmedicineHumansRapid Virologic ResponseHepatologyPeg-interferonbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CRecombinant Proteinsdigestive system diseasesDiscontinuationClinical trialTreatment OutcomeInfectious DiseasesWithholding TreatmentchemistryImmunologyChronic hepatitis C; Clinical trial; Peg-interferon; Ribavirin;FemaleViral hepatitisbusinessViral load
researchProduct

Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Si…

2020

BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls < 60 years of age at their first course of anti-TNF treatment. Data concerning persistence on therapy over the first year of treatment (primary objective) together …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaDrug-Related Side Effects and Adverse ReactionsKaplan-Meier EstimateAnti-Tumour Necrosis FactorDiseaseInflammatory bowel diseaseCohort Studies03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Treatment Failure030212 general & internal medicineAdverse effectAgedRetrospective StudiesAged 80 and overTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabAge FactorsAntibodies MonoclonalRetrospective cohort studyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisInfliximabSicilian Network for Inflammatory Bowel Diseases (SN-IBD).Withholding TreatmentConcomitantFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryCohort studyDrugs & Aging
researchProduct

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

2020

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had no…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesDiabetes mellitusInternal medicineAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetes; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding TreatmentDiabetes MellitusmedicineHumansHypoglycemic AgentsOutpatient clinicBenzhydryl CompoundsDapagliflozinObservationalAgedRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetesbusiness.industryType 2 diabetesRetrospective cohort studyMiddle Agedmedicine.diseasePharmacotherapyMetforminDiscontinuationDiabetes Mellitus Type 2Real-worldWithholding TreatmentchemistryTolerabilityAdherence030220 oncology & carcinogenesisFemalebusinessType 2medicine.drugJournal of Endocrinological Investigation
researchProduct

First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection

2010

A pandemic influenza A/H1N1v strain with the neuraminidase H274Y mutation was detected in nasal secretions of a 2-year-old leukemic patient with influenza-like illness after 18 days of treatment with oseltamivir. At baseline, no drug-resistant virus was found, while 4 days after treatment initiation a mix- ture of wild-type and mutated virus was detected. After treatment interruption, the wild type influenza virus re-emerged and became prevalent in nasal secretions after a few days, suggesting the lower fitness of the mutated virus strain. The patient slowly improved concurrently with a decrease in virus load, which resulted negative 42 days after diagnosis. No other drug-resistant influenz…

Bodily SecretionsvirusesResistanceDrug ResistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePandemic H1N1v Oseltamivir Resistancechemistry.chemical_compoundInfluenza A Virus H1N1 SubtypePandemicInfluenza A virusInfluenza A VirusViralChildViral LoadTreatment OutcomeInfectious DiseasesItalyChild PreschoolRNA ViralFemaleViral diseaseViral loadH1N1vSequence AnalysisH1N1v; Oseltamivir; Pandemic; Resistance; Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child Preschool; Female; Humans; Immunocompromised Host; Influenza A Virus H1N1 Subtype; Influenza Human; Italy; Molecular Sequence Data; Mutation Missense; Neuraminidase; Nose; Oseltamivir; RNA Viral; Sequence Analysis DNA; Treatment Outcome; Viral Load; Viral Proteins; Withholding Treatment; Drug Resistance Viral; Virology; Infectious DiseasesHumanOseltamivirMolecular Sequence DataMutation MissenseNeuraminidaseBiologyNoseAntiviral AgentsVirusresistanceImmunocompromised HostViral ProteinsOseltamivirVirologyDrug Resistance ViralInfluenza HumanmedicineHumansH1N1 SubtypePreschoolInfluenza-like illnessPandemicSequence Analysis DNADNAVirologyInfluenzaInfluenza; A/H1N1v; Oseltamivir; resistancechemistryAmino Acid SubstitutionWithholding TreatmentMutationbiology.proteinRNAA/H1N1vMissenseNeuraminidase
researchProduct

Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.

2020

Abstract Objective Minimize exposure to the SARS-CoV-2, reduce the chances of cross-transmission between patients and healthcare personnel, and prevent the development of postoperative complications from the management of patients with eye diseases during the 2019 coronavirus disease pandemic (COVID-19). Methods COVID-19 literature review and consensus establishment between different Spanish ophthalmology societies in order to provide guidelines and recommendations of maximum resources primarily conditioned by the state of alert, confinement and social distancing that occurs in Spain since March 16, 2020. Results The recommendations will promote the adoption of action and protection measure…

Eye DiseasesAtención oftalmológicaOphthalmologic Surgical ProceduresDiseaseRecommendationsPostoperative Complications0302 clinical medicineRisk FactorsHealth carePandemicOutpatient clinicMedicine030212 general & internal medicineSocieties Medicaleducation.field_of_studySocial distanceChloroquineGeneral MedicineEye careDisease ProgressionOftalmologíaMedical emergencySymptom AssessmentCoronavirus InfectionsAtención oftalmológica COVID-19 Eye care Oftalmología Ophthalmology Pandemia Pandemic Recomendaciones Recommendations SARS-CoV-2HydroxychloroquineInfectious Disease Transmission Patient-to-ProfessionalContact LensesBlood SafetyPneumonia ViralPopulationArticleAntimalarialsBetacoronavirus03 medical and health sciencesHumanseducationPandemicsPersonal protective equipmentPandemiaGovernmentPandemicSARS-CoV-2business.industryCOVID-19medicine.diseaseOphthalmologyWithholding TreatmentSpainAsymptomatic DiseasesRecomendaciones030221 ophthalmology & optometrybusiness
researchProduct

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwid…

2016

Background: Psoriasis induced by anti-tumor necrosis factor-alpha (TNF) therapy has been described as a paradoxical side effect. Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes geneticos y Ambientales registry of Grupo Espanol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with ant…

MaleAnti-Inflammatory AgentsInflammatory bowel diseaseGastroenterologyCohort Studies030207 dermatology & venereal diseases0302 clinical medicineCrohn DiseaseadalimumabImmunology and AllergyIncidence (epidemiology)IncidenceGastroenterologypsoriasisPrognosisside effectsCrohn's diseaseCohort030211 gastroenterology & hepatologyTumor necrosis factor alphaFemaleCohort studyAdultmedicine.medical_specialtyAdolescent03 medical and health sciencesGastrointestinal Agentsinflammatory bowel diseasePsoriasisInternal medicinemedicineHumansPsoriasisColitisulcerative colitisbusiness.industryTumor Necrosis Factor-alphaCase-control studyAdalimumabanti-TNFmedicine.diseaseInfliximabWithholding TreatmentSpainCase-Control StudiesPhysical therapyColitis UlcerativebusinessinfliximabFollow-Up Studies
researchProduct